Guidelines and EPA+DHA: Irreconcilable?

  Prof. Dr. C. von Schacky, Preventive Cardiology, Med Clinic I, University of Munich, and Omegametrix, Martinsried, both Germany. Email: Clemens.vonSchacky@med.uni-muenchen.de   Cardiac societies, like the American Heart Association (AHA) or the European Society of Cardiology (ESC) periodically publish guidelines, among them on primary or secondary prevention of cardiovascular disease (AHA) or cardiovascular prevention (ESC)

Read more...

Evaluating the Value of Stratification on Omega-3 LCPUFA Levels when the Randomized Controlled Testing Methodology is not Sufficiently Well-Controlled

This article at a glance This pilot study evaluated the concept that stratification of study participants can be useful for improving interpretations of the relationship between long-chain polyunsaturated fatty acid (LCPUFA) intake and biological effect. In patients scheduled for coronary artery bypass graft and/or heart valve replacement surgery, one group of individuals randomly assigned to

Read more...

Maternal Plasma Docosahexaenoic Acid (DHA) Concentrations Increase at the Critical Time of Neural Tube Closure

  Barbara J Meyer (University of Wollongong, Australia) Dilys J Freeman (University of Glasgow, UK)   Docosahexaenoic acid (DHA) and polyunsaturated fatty acid (PUFA) metabolism DHA is an omega-3 long chain polyunsaturated fatty acid (n-3 LCPUFA) containing 22 carbons and 6 carbon to carbon double bonds denoted as 22:6n-3. It is an n-3 fatty acid

Read more...

Look What’s New at Fats of Life

Dear Reader of Fats of Life. Welcome to 2017 and a new issue of Fats of Life, which brings exciting changes in our design. First of all, we have renamed the PUFA Newsletter to Fats of Life Newsletter, a change that had been pending for some time. We wanted to continue with the name “Fats

Read more...

Evaluating the Formation of Non-Enzymatic Oxidation Products of EPA and AA in a Population at Risk for Omega-3 Long-Chain Polyunsaturated Fatty Acid Deficiency

This article at a glance This study addressed the relationship between omega-3 status in the Inuit and the plasma levels of omega-3 LCPUFA-derived isoprostanes. EPA-derived isoprostane levels were positively related to omega-3 fatty acid status, and unrelated to cardiometabolic risk factors, unlike isoprostanes derived from arachidonic acid. Older Inuit that adhere more strongly to traditional

Read more...

Bronchopulmonary Dysplasia in Preterm Infants – Understanding the Physiological Changes in AA and DHA during Gestation

This article at a glance Bronchopulmonary dysplasia is a form of lung injury caused by assisted ventilation and oxygen support compounding an incomplete development of lung tissue observed in very early and low birth weight preterm infants. In a study of fetal fatty acid (LCPUFA) accretion during the third trimester of pregnancy, the level of

Read more...

Failure to Replicate Findings on Omega-3 LCPUFA Supplementation on the Transition to Psychotic Disorder in Individuals at Ultra-High Risk

This article at a glance Psychotic disorders encompass serious psychiatric disorders, manifesting themselves in the altered perception of reality, such as delusions or hallucinations, disorganized or bizarre behaviors and “negative” symptoms, which include flatness of emotion and interpersonal relations and amotivation. Psychotic disorders, when chronic, are characterized by low functioning and a poor prognosis. A

Read more...

Omega-3 LCPUFA Intake-Induced Molecular Changes in Type 2 Diabetes

This article at a glance The effects of omega-3 long-chain polyunsaturated fatty acids (LCPUFA) on deranged glucose homeostasis in type 2 diabetics are incompletely understood. Metabolomic analyses of blood samples from two recent randomized controlled clinical trials in American and Chinese adults with type 2 diabetes link omega-3 LCPUFA supplementation to changes in branched-chain amino

Read more...

A Multilayered Biomaterial for Vectorial Release of DHA-Derived RvD1 to Restrain Local Tissue Inflammatory Responses and Disorders

This article at a glance A thin, pliable, biodegradable multi-layered material incorporating the DHA-derived lipid mediator resolvin D1 (RvD1) was developed. The thin-film device allowed sustained diffusion of RvD1 from the surface with the lowest copolymer density, permitting one-sided release. RvD1 could be released from the thin-film device into arterial tissue, and activated anti-inflammatory, anti-proliferative

Read more...